By
Motley Fool Staff
|
More Articles
June 12, 2008
|
It's typically feast or famine when it comes to biotech stocks, but one big winner can more than make up for a bunch of losers. The secret is finding well-run companies delivering high-quality drugs before the market finds them.
Of course, that's easier said than done, and some biotech companies are already beyond their high-growth stage. Nevertheless, in that spirit, we'll use the aggregate intelligence of the 105,000-plus investors participating in Motley Fool CAPS to find biotech stocks that the community likes -- those with four- and five-star ratings. The community's approval could be a sign that further research is in order.
Here are five such stocks:
|
Company
|
Market Cap
|
% CAPS All-Star Bulls
|
CAPS Rating
(Out of 5)
|
CAPS Research
|
|
Amgen (Nasdaq: AMGN )
|
$46.8 B
|
94.3%
|
****
|
AMGN
|
|
Genentech (NYSE: DNA )
|
$77.7 B
|
96.3%
|
****
|
DNA
|
|
Genzyme (Nasdaq: GENZ )
|
$17.4 B
|
95.1%
|
*****
|
GENZ
|
|
ViroPharma (Nasdaq: VPHM )
|
$697 M
|
98.3%
|
*****
|
VPHM
|
|
Gilead Sciences (Nasdaq: GILD )
|
$49.0 B
|
97.6%
|
*****
|
GILD
|
Source: Motley Fool CAPS, as of June 11, 2008.
Come and join us on CAPS to learn more about these and countless other interesting stock ideas. Sign up for free.
RSS Headlines
Fool UK